Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

PURPOSE: It has been postulated that castration-resistant prostate cancer (CRPC) commonly remains hormone dependent. Abiraterone acetate is a potent, selective, and orally available inhibitor of CYP17, the key enzyme in androgen and estrogen biosynthesis. PATIENTS AND METHODS: This was a phase I/II...

Full description

Saved in:
Bibliographic Details
Main Authors: Attard, Gerhardt, Reid, Alison H.M., A’Hern, Roger, Parker, Christopher, Oommen, Nikhil Babu, Folkerd, Elizabeth, Messiou, Christina, Molife, L. Rhoda, Maier, Gal, Thompson, Emilda, Olmos, David, Sinha, Rajesh, Lee, Gloria, Dowsett, Mitch, Kaye, Stan B., Dearnaley, David, Kheoh, Thian, Molina, Arturo, de Bono, Johann S.
Format: Artigo
Language:Inglês
Published: 2009
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3535569/
https://ncbi.nlm.nih.gov/pubmed/19470933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.0642
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items